AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX202.13+1.35 (+0.67%) ▲|SBUX105.82-0.90 (-0.84%) ▼|SCHW110.38+2.14 (+1.98%) ▲|SO88.77+0.46 (+0.52%) ▲|SPG211.52+1.32 (+0.63%) ▲|T26.19+0.24 (+0.92%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN253.83-0.97 (-0.38%) ▼|UBER75.96-0.49 (-0.64%) ▼|UNH400.94+1.28 (+0.32%) ▲|UNP289.15-0.58 (-0.20%) ▼|UPS103.50+0.49 (+0.48%) ▲|USB63.53+0.76 (+1.21%) ▲|V378.75+0.35 (+0.09%) ▲|VZ50.59+0.37 (+0.74%) ▲|WFC89.19-0.08 (-0.09%) ▼|WMT108.42+2.33 (+2.20%) ▲|XOM162.21-1.94 (-1.18%) ▼|AAPL328.21+3.25 (+1.00%) ▲|ABBV260.21-1.51 (-0.58%) ▼|ABT108.79-1.68 (-1.52%) ▼|ACN193.12+5.44 (+2.90%) ▲|ADBE285.75+5.96 (+2.13%) ▲|AMAT435.91-2.55 (-0.58%) ▼|AMD456.16-0.90 (-0.20%) ▼|AMGN444.12+1.28 (+0.29%) ▲|AMT177.75+4.83 (+2.79%) ▲|AMZN258.90+3.92 (+1.54%) ▲|AVGO357.16-10.08 (-2.74%) ▼|AXP329.82-0.16 (-0.05%) ▼|BA210.51+1.64 (+0.79%) ▲|BAC63.04+0.44 (+0.70%) ▲|BKNG195.13-4.47 (-2.24%) ▼|BLK1,126.15+19.07 (+1.72%) ▲|BMY68.09+0.43 (+0.64%) ▲|BNY164.33+2.29 (+1.41%) ▲|BRK-B508.13+2.89 (+0.57%) ▲|C138.14+3.80 (+2.83%) ▲|CAT800.14+7.86 (+0.99%) ▲|CL90.09-0.01 (-0.01%) ▼|CMCSA26.65-0.16 (-0.60%) ▼|COF220.50+3.90 (+1.80%) ▲|COP135.72-1.48 (-1.08%) ▼|COST925.41-3.07 (-0.33%) ▼|CRM264.43+7.50 (+2.92%) ▲|CSCO108.61-0.85 (-0.77%) ▼|CVS97.20-0.03 (-0.03%) ▼|CVX211.32-0.46 (-0.22%) ▼|DE694.41-3.96 (-0.57%) ▼|DHR211.03+1.12 (+0.53%) ▲|DIS107.16-0.82 (-0.76%) ▼|DUK121.40+0.84 (+0.70%) ▲|EMR150.21+1.23 (+0.83%) ▲|FDX324.31+7.77 (+2.45%) ▲|GD365.87+1.80 (+0.49%) ▲|GE333.48+3.98 (+1.21%) ▲|GEV941.84+19.90 (+2.16%) ▲|GILD151.22+1.61 (+1.08%) ▲|GM87.22+2.35 (+2.77%) ▲|GOOG339.08+5.30 (+1.59%) ▲|GOOGL342.48+5.36 (+1.59%) ▲|GS1,037.93+33.51 (+3.34%) ▲|HD318.07+1.89 (+0.60%) ▲|HON207.63+1.56 (+0.76%) ▲|IBM234.71+3.01 (+1.30%) ▲|INTC91.67+1.62 (+1.80%) ▲|INTU344.30+1.36 (+0.40%) ▲|ISRG369.83-2.05 (-0.55%) ▼|JNJ278.43+3.22 (+1.17%) ▲|JPM362.06+5.84 (+1.64%) ▲|KO88.81+0.57 (+0.65%) ▲|LIN482.19-3.66 (-0.75%) ▼|LLY1,159.60-0.48 (-0.04%) ▼|LMT532.95+1.40 (+0.26%) ▲|LOW201.90+2.06 (+1.03%) ▲|LRCX292.66+4.34 (+1.51%) ▲|MA585.71-2.43 (-0.41%) ▼|MCD259.63-1.32 (-0.51%) ▼|MDLZ61.45-1.00 (-1.60%) ▼|MDT93.10+0.92 (+1.00%) ▲|META610.68+17.83 (+3.01%) ▲|MMM168.31-0.44 (-0.26%) ▼|MO69.49-0.07 (-0.10%) ▼|MRK152.34+0.70 (+0.46%) ▲|MS217.15+5.33 (+2.52%) ▲|MSFT510.12+13.30 (+2.68%) ▲|MU958.16+2.08 (+0.22%) ▲|NEE84.06+0.96 (+1.16%) ▲|NFLX82.67-0.06 (-0.07%) ▼|NKE38.77+0.53 (+1.39%) ▲|NOW145.59+8.87 (+6.49%) ▲|NVDA228.45+4.04 (+1.80%) ▲|ORCL154.04+8.29 (+5.69%) ▲|PEP140.02-0.50 (-0.36%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG146.92-0.72 (-0.49%) ▼|PLTR182.53+13.07 (+7.71%) ▲|PM186.17-1.77 (-0.94%) ▼|QCOM168.57-0.47 (-0.28%) ▼|RTX202.13+1.35 (+0.67%) ▲|SBUX105.82-0.90 (-0.84%) ▼|SCHW110.38+2.14 (+1.98%) ▲|SO88.77+0.46 (+0.52%) ▲|SPG211.52+1.32 (+0.63%) ▲|T26.19+0.24 (+0.92%) ▲|TMO618.43+9.89 (+1.63%) ▲|TMUS188.02+0.72 (+0.38%) ▲|TSLA376.37+19.36 (+5.42%) ▲|TXN253.83-0.97 (-0.38%) ▼|UBER75.96-0.49 (-0.64%) ▼|UNH400.94+1.28 (+0.32%) ▲|UNP289.15-0.58 (-0.20%) ▼|UPS103.50+0.49 (+0.48%) ▲|USB63.53+0.76 (+1.21%) ▲|V378.75+0.35 (+0.09%) ▲|VZ50.59+0.37 (+0.74%) ▲|WFC89.19-0.08 (-0.09%) ▼|WMT108.42+2.33 (+2.20%) ▲|XOM162.21-1.94 (-1.18%) ▼|
27.2 C
New York
Friday, September 4, 2026

Tag: clinical study

newssourceFORcompanyinformationcontent1releasesmarket

Levicept to Present Data Suggesting LEVI-04 May Modify Disease in Osteoarthritis at EULAR 2026

Further clinical efficacy and pharmacology data also to be presented 
Further clinical efficacy and pharmacology data also to be presented

Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and...

Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026

CHENGDU, China, June 3, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 American Society...

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with...

Châtillon, France, June 2, 2026

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

Veterinarian-Founded Startup Prodogi Launches First Oral Health Strip for Dogs with Slow Dissolve Technology

First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...

Jabez Biosciences, Inc. Opens Second Clinical Site in Phase 1 Oncology Clinical Study of JBZ-001

Jabez Biosciences Announces Opening of Second Clinical Site in Phase 1 study in Solid Tumors and NHL

AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Continued progress across pipeline programs with focus on pancreatic cancer

Natural DHT Blockers Take Center Stage in Hair Loss Defense — HairSmart Leads the Charge with Award-Winning Formula

HairSmart’s award-winning natural DHT Blocker offers a safe, plant-based solution to combat hair loss, clinically proven, side-effect-free, and effective.

Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights

- Dosed first patient in SURF302 for intermediate risk non-muscle invasive bladder cancer (IR NMIBC) - - Cash, cash equivalents, and marketable securities of $296.3...

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren’s Syndrome in China

YANTAI, China, Aug. 13, 2025 /PRNewswire/ -- On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical study

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers